GlassScriptPhysician profile
Scott S Propeck
NPI 1255342598
$4,230.30
in general payments reported to CMS, 2019-2025
25 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $293 · 2021: $1,372 · 2022: $1,178 · 2023: $606 · 2024: $204 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.32 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $877.49 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $523.94 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $388.44 | 2019-2023 | |
| Boston Scientific Corporation | $258.47 | 2023-2024 | Resolution 360 Ultra Clip, Axios |
| Nestle Healthcare Nutrition INC. | $237.30 | 2020-2023 | |
| Celgene Corporation | $208.77 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $153.44 | 2020-2023 | Dificid |
| Mauna Kea Technologies, INC. | $152.25 | 2021-2022 | |
| Conmed Corporation | $115.69 | 2025 | Conmed Biliary |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.75 | 2020-2022 | |
| Redhill Biopharma INC. | $65.39 | 2020-2021 | |
| Micro-Tech Endoscopy USA, INC. | $55.87 | 2021-2022 | |
| Amgen INC. | $40.71 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $34.55 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.48 | 2022 | |
| Intercept Pharmaceuticals, INC. | $28.23 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $23.21 | 2021 | |
| Sandoz INC. | $22.89 | 2024 | Hyrimoz |
| La Jolla Pharmaceutical Company | $14.69 | 2021 | |
| Fresenius Kabi USA, LLC | $13.07 | 2023 | |
| Braintree Laboratories, INC. | $11.69 | 2022 | |
| Qol Medical, LLC | $10.02 | 2019 | |
| Romark Laboratories, Lc | $1.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Propeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.